How do you approach adjuvant chemotherapy in patients with resected pancreatic adenocarcinoma?  

For my good performance status patients, I offer gem/cap as per the ESPAC-4 trial. Though the incremental benefit is modest, it was statistically significant and the toxicities associated with the combination are quite manageable most of the time. I look forward to the results of three other adjuvan...

For resected pancreas cancer - the ESPAC-4 data for gemcitabine/capecitabine support the use of this regimen and outside of a trial setting, this combination represents a new standard option for this disease. We now routinely use this regimen in practice. Nonetheless given pending data on other mult...

The main take away from PRODIGE24 further support the role for adjuvant chemotherapy with an added benefit for FOLFIRINOX. For good performance status patients, I would recommend FOLFIRINOX chemotherapy, which showed a significant improvement in disease free survival and overall survival compared t...